Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levallorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 10/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.86 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.69 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.69 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.69 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.69 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.69 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.69 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levallorphan SCHEMBL20505815 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL12232843 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL29368769 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL209271 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL34060 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL12233279 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL16311899 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Dextallorphan SCHEMBL29438705 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL8459964 | 0.99 | OPRM1 (0.98) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL5675160 | 0.97 | OPRM1 (0.94) | OPRM1OPRK1KCNH2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | Molokanova, Elena (US) | 2026-02-03 | — | — | US | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| US-20240350432-A1 | CENTRAL NERVOUS SYSTEM MODULATORS AS COVID-19 THERAPEUTICS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, | 2024-10-24 | — | — | US | claimed |
| US-20240350433-A1 | TREATMENT COMPOSITIONS AND METHODS | UNIV YALE (US) | 2024-10-24 | — | — | US | claimed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| US-20240066003-A1 | NEURODEVELOPMENTAL DISORDER THERAPY | ANAVEX LIFE SCIENCES CORP. (US) | 2024-02-29 | — | — | US | claimed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| WO-2023023038-A1 | TREATMENT COMPOSITIONS AND METHODS | YALE UNIVERSITY (US) | 2023-02-23 | — | — | WO | claimed |
| US-20220401366-A1 | LONG ACTING NMDA ANTAGONISTS | CONSEGNA PHARMA INC (US) | 2022-12-22 | — | — | US | claimed |
| EP-2841067-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | The Regents of The University of California (US) | 2015-03-04 | — | — | EP | claimed |
| WO-2014117089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-31 | — | — | WO | claimed |
| US-20140050789-A1 | MITIGATION OF EPILEPTIC SEIZURES BY COMBINATION THERAPY USING BENZODIAZEPINES AND NEUROSTEROIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-20 | — | — | US | claimed |
| WO-2014028398-A2 | MITIGATION OF EPILEPTIC SEIZURES BY COMBINATION THERAPY USING BENZODIAZEPINES AND NEUROSTEROIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-20 | — | — | WO | claimed |
| WO-2014015047-A1 | COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-01-23 | — | — | WO | claimed |
| WO-2013163455-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-31 | — | — | WO | claimed |
| WO-2013138118-A1 | TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-19 | — | — | WO | claimed |
| EP-1091759-B1 | COMPOSITION FOR THE INDUCTION OF APOPTOSIS IN TARGET CELLS | UNIV DUNDEE (GB) | 2012-10-24 | — | — | EP | claimed |
| US-20120129879-A1 | Compounds and Compositions for Use in Phototherapy and in Treatment of Ocular Neovascular Disease and Cancers | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2012-05-24 | — | — | US | claimed |
| WO-2011009020-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | MALLINCKRODT INC. (US) | 2011-01-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | GRIN2B, GRIN2A, GRIN3A | OPRM1 265/4885OPRK1 373/4885KCNH2 349/4885 |
| US-20140050789-A1 | MITIGATION OF EPILEPTIC SEIZURES BY COMBINATION THERAPY USING BENZODIAZEPINES AND NEUROSTEROIDS | GABRB2, GABRA4, GABRB1 | OPRM1 528/4885OPRK1 346/4885KCNH2 439/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | OPRM1 50/4885OPRK1 41/4885KCNH2 1500/4885 |
| US-20120129879-A1 | Compounds and Compositions for Use in Phototherapy and in Treatment of Ocular Neovascular Disease and Cancers | VEGFA, OPRL1, OGFR | OPRM1 5/4885OPRK1 4/4885KCNH2 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.